Geron Provides Update on Phase 3 Imetelstat Trial
Geron Corporation provided an update on its Phase 3 IMpactMF clinical trial of imetelstat in relapsed/refractory myelofibrosis.
Related stories
Giant Network Q3 Net Profit Rises 16.0% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
Bending Spoons Raises $330 Million in Private Placement With Berkshire Hathaway
Bending Spoons raised $330 million in a private placement with Berkshire Hathaway.
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
Alnylam Pharmaceuticals Q3 2026 Earnings Call Begins
Alnylam Pharmaceuticals' quarterly earnings call has begun.
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
China Citic Bank Q3 Net Profit Rises 4.60% Y/Y
M impact | EQUITY | Oct 29, 2026, 12:27 PM UTC
Stagwell Beats Q3 EPS by $0.03, Misses Revenue; FY26 EPS Guidance In Line
Stagwell reported Q3 earnings of $0.34 per share, excluding non-recurring items, $0.03 above expectations. Revenue missed, and FY26 EPS guidance was in line.
M impact | EQUITY | Oct 29, 2026, 12:27 PM UTC
Nokian Tyres Publishes Q3 2026 Results Call Transcript
M impact | EQUITY | Oct 29, 2026, 12:27 PM UTC